260 related articles for article (PubMed ID: 36774337)
1. The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.
Diazzi S; Tartare-Deckert S; Deckert M
Oncogenesis; 2023 Feb; 12(1):7. PubMed ID: 36774337
[TBL] [Abstract][Full Text] [Related]
2. Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.
Diazzi S; Tartare-Deckert S; Deckert M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466585
[TBL] [Abstract][Full Text] [Related]
3. A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.
Girard CA; Lecacheur M; Ben Jouira R; Berestjuk I; Diazzi S; Prod'homme V; Mallavialle A; Larbret F; Gesson M; Schaub S; Pisano S; Audebert S; Mari B; Gaggioli C; Leucci E; Marine JC; Deckert M; Tartare-Deckert S
Cancer Res; 2020 May; 80(10):1927-1941. PubMed ID: 32179513
[TBL] [Abstract][Full Text] [Related]
4. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V; Boivin F; Dalle S; Caramel J
Front Immunol; 2022; 13():873116. PubMed ID: 35432344
[TBL] [Abstract][Full Text] [Related]
5. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.
Huang F; Santinon F; Flores González RE; Del Rincón SV
Front Oncol; 2021; 11():756001. PubMed ID: 34604096
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
[TBL] [Abstract][Full Text] [Related]
7. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.
Rubanov A; Berico P; Hernando E
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497341
[TBL] [Abstract][Full Text] [Related]
9. Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma.
Berestjuk I; Lecacheur M; Carminati A; Diazzi S; Rovera C; Prod'homme V; Ohanna M; Popovic A; Mallavialle A; Larbret F; Pisano S; Audebert S; Passeron T; Gaggioli C; Girard CA; Deckert M; Tartare-Deckert S
EMBO Mol Med; 2022 Feb; 14(2):e11814. PubMed ID: 34957688
[TBL] [Abstract][Full Text] [Related]
10. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge.
Florent L; Saby C; Slimano F; Morjani H
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174072
[TBL] [Abstract][Full Text] [Related]
12. Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.
Zhou L; Yang K; Andl T; Wickett RR; Zhang Y
J Cancer; 2015; 6(8):717-26. PubMed ID: 26185533
[TBL] [Abstract][Full Text] [Related]
13. Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.
Popovic A; Tartare-Deckert S
Front Oncol; 2022; 12():924553. PubMed ID: 36119516
[TBL] [Abstract][Full Text] [Related]
14. Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies.
Pizzimenti S; Ribero S; Cucci MA; Grattarola M; Monge C; Dianzani C; Barrera G; Muzio G
Antioxidants (Basel); 2021 Dec; 10(12):. PubMed ID: 34943045
[TBL] [Abstract][Full Text] [Related]
15. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
[TBL] [Abstract][Full Text] [Related]
16. Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes.
Hodgkinson A; Trucu D; Lacroix M; Le Cam L; Radulescu O
Front Oncol; 2022; 12():857572. PubMed ID: 35494017
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.
Massi D; Mihic-Probst D; Schadendorf D; Dummer R; Mandalà M
Cancer Treat Rev; 2020 Aug; 88():102060. PubMed ID: 32619863
[TBL] [Abstract][Full Text] [Related]
19. The Emerging Therapeutic Landscape of Advanced Melanoma.
Henriques V; Martins T; Link W; Ferreira BI
Curr Pharm Des; 2018; 24(5):549-558. PubMed ID: 29366407
[TBL] [Abstract][Full Text] [Related]
20. New Insights into the Phenotype Switching of Melanoma.
Pagliuca C; Di Leo L; De Zio D
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
